Archimedes
Elaine Tucker has a strong background in pharmacy, with experience in clinical services, consulting, and retail pharmacy settings. As Vice President of Clinical Services at Archimedes, Elaine provides oversight and improvement in client-specific populations and industry trends. With previous roles as a Staff Pharmacist at Walmart and a Consulting Pharmacist at PillarRx Consulting, Elaine has a diverse skill set including prescription verification, clinical counseling, medication therapy management, and staff training. With a Doctor of Pharmacy degree from University of Health Sciences and Pharmacy in St. Louis and a Bachelor of Science in Biochemistry and Molecular Biology from Bellarmine University, Elaine Tucker is a highly qualified professional in the pharmacy field.
Archimedes
Specialty drug spend is the single fastest growing healthcare expense. Recognizing the potential clinical value of these drugs, plan sponsors want to provide them to their enrollees—but to maintain an affordable, sustainable benefit in this rapidly changing environment, they must also control costs. To do this, plan sponsors need quantitative information about which strategies work to target drugs to those in need of them and they must minimize use of clinically ineffective therapies and reduce waste. However, the guidance and services provided to plan sponsors to achieve these goals is not always objective or complete. Recognizing these challenges, Archimedes offers specialty drug management solutions for health plans, TPAs, employers, labor groups, and other plan sponsors across the U.S, without any potential conflicted financial relationships with specialty pharmacies or PBMs. Like the scientist and inventor who provided the inspiration for our name, we leverage an unmatched combination of analytic expertise, technological capabilities, experience, and pragmatism to provide plan sponsors with the support that they really need to control the growing cost of specialty drugs across the pharmacy and medical benefits. Fundamental to our business is the belief that full visibility into the economics and clinical performance of a specialty drug program is critical to making informed decisions concerning specialty drug management.